Please be advised that the site will be down for maintenance on Sunday, September 1, 2024, from 08:00 to 18:00, and again on Monday, September 2, 2024, from 08:00 to 09:00. We apologize for any inconvenience this may cause.
dc.contributor.author | Risenga, Samuel Malamulele![]() |
|
dc.contributor.author | Kriel, M.![]() |
|
dc.contributor.author | Karabus, S.![]() |
|
dc.contributor.author | Manjra, Ahmed I.![]() |
|
dc.contributor.author | Gray, Claudia L.![]() |
|
dc.contributor.author | Goddard, E.![]() |
|
dc.contributor.author | Lang, A.C.![]() |
|
dc.contributor.author | Terblanche, Alta J.![]() |
|
dc.contributor.author | Van der Spuy, D.A.![]() |
|
dc.contributor.author | Levin, M.E.![]() |
|
dc.date.accessioned | 2015-03-03T05:59:42Z | |
dc.date.available | 2015-03-03T05:59:42Z | |
dc.date.issued | 2015-01 | |
dc.description.abstract | An anaphylactic reaction may be fatal if not recognised and managed appropriately with rapid treatment. Key steps in the management of anaphylaxis include eliminating additional exposure to the allergen, basic life-support measures and prompt intramuscular administration of adrenaline 0.01 mg/kg (maximum 0.5 mL). Adjunctive measures include nebulised bronchodilators for lower-airway obstruction, nebulised adrenaline for stridor, antihistamines and corticosteroids. Patients with an anaphylactic reaction should be admitted to a medical facility so that possible biphasic reactions may be observed and risk-reduction strategies initiated or reviewed after recovery from the acute episode. Factors associated with increased risk of severe reactions include co-existing asthma (and poor asthma control), previous severe reactions, delayed administration of adrenaline, adolescents and young adults, reaction to trace amounts of foods, use of non-selective β-blockers and patients who live far from medical care. Risk-reduction measures include providing education with regard to food allergy and a written emergency treatment plan on allergen avoidance, early symptom recognition and appropriate emergency treatment. Risk assessment allows stratification with provision of injectable adrenaline (preferably via an auto-injector) if necessary. Patients with ambulatory adrenaline should be provided with written instructions regarding the indications for and method of administration of this drug and trained in its administration. Patients and their caregivers should be instructed about how to avoid foods to which the former are allergic and provided with alternatives. Permission must be given to inform all relevant caregivers of the diagnosis of food allergy. The patient must always wear a MedicAlert necklace or bracelet and be encouraged to join an appropriate patient support organisation. | en_ZA |
dc.description.librarian | hb2015 | en_ZA |
dc.description.uri | http://www.samj.org.za | en_ZA |
dc.identifier.citation | Risenga, SM, Kriel, M, Karabus, S, Manjra, AI, Gray, CL, Goddard, E, Lang, AC, Terblanche, AJ, Van der Spuy, DA & Levin, ME 2015, 'Severe food allergy and anaphylaxis : treatment, risk assessment and risk reduction', South African Medical Journal , vol. 105, no. 1, pp. 72-73. | en_ZA |
dc.identifier.issn | 0256-9574 (print) | |
dc.identifier.issn | 2078-5135 (online) | |
dc.identifier.issn | 10.7196/SAMJ.9099 | |
dc.identifier.uri | http://hdl.handle.net/2263/43838 | |
dc.language.iso | en | en_ZA |
dc.publisher | Health and Medical Publishing Group | en_ZA |
dc.rights | © 2015 Health & Medical Publishing Group. This work is licensed under a Creative Commons Attribution-NonCommercial Works License (CC BY-NC 3.0). | en_ZA |
dc.subject | Severe food allergy | en_ZA |
dc.subject | Anaphylaxis | en_ZA |
dc.subject | Treatment | en_ZA |
dc.subject | Risk assessment | en_ZA |
dc.subject | Risk reduction | en_ZA |
dc.subject | Allergic reactions to foods | en_ZA |
dc.title | Severe food allergy and anaphylaxis : treatment, risk assessment and risk reduction | en_ZA |
dc.type | Article | en_ZA |